Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies.
作者： Fuping Gao , Lei Li , Huizhu Zhang , Wenzhi Yang , Hongli Chen
DOI: 10.1016/J.IJPHARM.2010.03.044
关键词:
摘要: Deoxycholic acid hydrophobically modified-carboxymethylated-curdlan (DCMC) conjugate was developed as a novel carrier for the anticancer drugs. Epirubicin (EPB), model drug, physically loaded into DCMC self-assembled nanoparticles. EPB-loaded nanoparticles were almost spherical in shape and their size, range of 327.4-511.5 nm, increased with EPB-loading content increasing. In vitro release EPB from showed sustained drug pattern rate related to pH media loading content. The cytotoxic activity assayed by MTT colorimetric assay. Compared free higher cytotoxicity, which may be attributed enhanced cellular uptake. vivo toxicity study indicated that did not induce unexpected side effects. Tissue biodistribution performed tumor-bearing mice. result uptake tumor decreased kidney heart, compared drug. Moreover, volume reductions induced conjugate, EDNs 24.3%, 58.9% 70%, respectively, suggested could effectively retard growth tumor.
core.ac.uk
elsevier.com
sci-hub.se 参考文章(30)
Andreas Greinacher, Susanne Alban, Veronika Dummel, Gerhard Franz, Christian Mueller-Eckhardt, Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thrombosis and Haemostasis. ,vol. 74, pp. 886- 892 ,(1995) , 10.1055/S-0038-1649842
Kazuo Nitta, Yukio Sugino, Takuma Sasaki, Noriko Abiko, Dependence on chain length of antitumor activity of (1 leads to 3)-beta-D-glucan from Alcaligenes faecalis var. myxogenes, IFO 13140, and its acid-degraded products. Cancer Research. ,vol. 38, pp. 379- 383 ,(1978)
R J Cersosimo, W K Hong, Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. Journal of Clinical Oncology. ,vol. 4, pp. 425- 439 ,(1986) , 10.1200/JCO.1986.4.3.425
K. Y. Lee, J.-H. Kim, I. C. Kwon, S. Y. Jeong, Self-aggregates of deoxycholic acid-modified chitosan as a novel carrier of adriamycin Colloid and Polymer Science. ,vol. 278, pp. 1216- 1219 ,(2000) , 10.1007/S003960000389
Jong-Ho Kim, Yoo-Shin Kim, Sungwon Kim, Jae Hyung Park, Kwangmeyung Kim, Kuiwon Choi, Hesson Chung, Seo Young Jeong, Rang-Woon Park, In-San Kim, Ick Chan Kwon, Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. Journal of Controlled Release. ,vol. 111, pp. 228- 234 ,(2006) , 10.1016/J.JCONREL.2005.12.013
F GAO, H ZHANG, L LIU, Y WANG, Q JIANG, X YANG, Q ZHANG, Preparation and physicochemical characteristics of self-assembled nanoparticles of deoxycholic acid modified-carboxymethyl curdlan conjugates Carbohydrate Polymers. ,vol. 71, pp. 606- 613 ,(2008) , 10.1016/J.CARBPOL.2007.07.008
C. J. T. Hoes, P. J. Boon, F. Kaspersen, E. S. Bos, J. Feijen, Design of soluble conjugates of biodegradable polymeric carriers and adriamycin Macromolecular Symposia. ,vol. 70, pp. 119- 136 ,(1993) , 10.1002/MASY.19930700115
Peggy Chan, Motoichi Kurisawa, Joo Eun Chung, Yi-Yan Yang, None, Synthesis and characterization of chitosan-g-poly(ethylene glycol)-folate as a non-viral carrier for tumor-targeted gene delivery. Biomaterials. ,vol. 28, pp. 540- 549 ,(2007) , 10.1016/J.BIOMATERIALS.2006.08.046
Takashi Yoshida, Yuichi Yasuda, Toshiyuki Uryu, Hideki Nakashima, Naoki Yamamoto, Toru Mimura, Yutaro Kaneko, Synthesis and in vitro inhibitory effect of L-glycosyl-branched curdlan sulfates on AIDS virus infection Macromolecules. ,vol. 27, pp. 6272- 6276 ,(1994) , 10.1021/MA00100A007
Y Yoshitomi, Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Letters. ,vol. 207, pp. 165- 174 ,(2004) , 10.1016/J.CANLET.2003.11.037